CDER appointment
This article was originally published in The Tan Sheet
Executive Summary
Douglas Throckmorton, MD, is appointed to the permanent post of CDER Deputy Director, FDA's Center for Drug Evaluation & Research announces Sept. 22. Throckmorton has been acting in the position since May 2004 (1"The Tan Sheet" April 19, 2004, p. 9). Throckmorton started at FDA in 1997 as a medical officer in the Division of Cardiovascular & Renal Drug Products, became deputy director of the division in 2000 and was appointed division director in 2002. "Doug's medical, regulatory and leadership skills make him an outstanding addition to CDER's senior management team and I am honored that he has agreed to continue as my deputy," CDER Director Stephen Galson states...
You may also be interested in...
FDA Cardio-Renal Head Throckmorton Named CDER Acting Deputy
FDA Cardio-Renal Drug Products Division Director Douglas Throckmorton, MD, is moving up to the position of acting deputy director of CDER, effective May 3
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.